GLP1R and type 2 diabetes mellitus: In recent years, cardiovascular risk reduction in patients with T2D has significantly improved with the advent of newer pharmacological agents, including sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs).